The emerging role of vedolizumab in the treatment of ulcerative colitis. (December 2012)

• Record Type: Journal Article
• Authors: Mosli, Mahmoud H; Feagan, Brian G
• Is Part Of: Clinical investigation. Volume 2:Number 12(2012)
• Page Start: 1201
• Page End: 1212
• Publication Date: 2012-12
• Subjects: α4β7 integrin -- MAdCAM-1 -- therapy -- ulcerative colitis -- vedolizumab; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical trials -- Periodicals; 615.580724
• DOI: 10.4155/cli.12.119
• Languages: English
• ISSNs: 2041-6806

Abstract

Ulcerative colitis is a chronic inflammatory disorder of unknown etiology. Despite current treatments that include aminosalicylates, corticosteroids, antimetabolites and TNF antagonists, many patients fail to respond to conventional medical management and undergo colectomy. Thus, new approaches to treatment are needed. This review discusses the emerging role of vedolizumab, a humanized monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of ulcerative colitis.